Rosengren et al. (1996) first tested NfPs as possible biomarkers using enzyme-linked immunosorbent assay (ELISA) with polyclonal rabbit antisera specific against the individual NfPs and showed that CSF NfL levels were increased in patients with ALS and AD compared to controls. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.